Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the schizophrenia health outcomes (SOHO) study

Value in Health

Volumn 12, Issue 4, 2009, Pages 536-543

  Alonso, Jordi ^a,b   Croudace, Tim ^c   Brown, Jacqueline ^d   Gasquet, Isabelle ^e   Knapp, Martin R J ^f,g   Suárez, David ^h   Novick, Diego ^d  

^a HOSPITAL DEL MAR   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

^e HÔPITAL PAUL BROUSSE   (France)

^f LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

Antipsychotics; Health related quality of life; Outpatients; Schizophrenia

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; DISEASE COURSE; DOSE TIME EFFECT RELATION; EMPLOYMENT STATUS; EUROPE; EUROPEAN QUALITY OF LIFE QUESTIONNAIRE 5D; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL BEHAVIOR; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; CONFIDENCE INTERVALS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, ECONOMIC; MULTIVARIATE ANALYSIS; OUTPATIENTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISPERIDONE; SCHIZOPHRENIA; SPAIN; TIME FACTORS;

EID: 60549091870     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00495.x     Document Type: Article

References (38)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003 60 : 553 64.
2. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002 57 : 201 8.
3. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999 8 : 417 26.
4. Tunis SL, Croghan TW, Heliman DK, et al. Reliability, validity and application of the medical outcome study SF-36 short form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999 37 : 678 91.
5. Rosenheck R, Perlich D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003 290 : 2693 702.
6. Ristner M, Gible A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004 24 : 582 91.
7. Kilian R, Dietrich S, Toumi M, et al. Quality of life in persons with schizophrenia in outpatient treatment with first- or second-generation antipsychotics. Acta Psychiatr Scand 2004 110 : 108 18.
8. Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005 111 : 106 15.
9. Strakowski SM, Johnson JL, DelBello MP, et al. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res 2005 78 : 161 9.
10. Beasley CM, Sutton VK, Taylor CC, et al. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? J Clin Psychopharmacol 2006 26 : 40 4.
11. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication and side effects. J Clin Psychiatry 2004 65 : 932 9.
12. Haro JM, Suárez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007 17 : 235 44.
13. Covell NH, Frisman LK, Essock SM. Rates of refusal to participate in research studies among men and women. Psychiatr Serv 2003 54 : 1541 4.
14. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 17 : 2265 81.
15. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 70 : 41 55.
16. Haro JM, Kontodimas S, Negrin MA, et al. Methodological aspects in the assessment of treatment effects in observational health outcome studies. Appl Health Econ Health Policy 2006 5 : 11 25. (Pubitemid 43927196)
17. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003 107 : 222 32.
18. Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005 111 : 220 31.
19. Haro JM, Novick D, Belger M, Jones PB. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry 2006 21 : 41 7.
20. Haro JM, Novick D, Suárez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006 26 : 571 8.
21. Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Dordrecht, The Netherlands : Kluwer Academic Publishers, 2003.
22. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D [Working Paper #172 York, UK : York Centre for Health Economics, 1999.
23. Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. Annu Rev Public Health 2002 23 : 151 69.
24. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002 28 : 17 29. (Pubitemid 34534747)
25. Windmeijer F, Kontodimas S, Knapp M, et al. Methodological approach for assessing the cost-effectiveness of treatments using longitudinal observational data: the SOHO study. Int J Technol Assess Health Care 2006 22 : 460 8.
26. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982 38 : 963 74.
27. Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics 2008 26 : 341 58.
28. Szende A, Williams A. Measuring Self Reported Population Health: An International Perspective Based on the EQ-5D. Budapest, Hungary : SpringMed Publication Ltd, 2004.
29. Silva de Lima M, de Jesús Mari J, Breier A, et al. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first generation antipsychotics. J Clin Psychiatry 2005 66 : 831 8.
30. Lieberman JA, Scott Stroup T, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 23.
31. Loebel AD, Warrington L, Siu C, Lieberman JA. Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone vs. haloperidol treatment in a 40-week core and 3-year double-blind extension study. Abstract NR395. Program and Abstracts of American Psychiatric Assoc Annual Meeting, May 20-25 2006, Toronto, Ontario, Canada, 2006.
32. Ritsner MS, Gibel A. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: a 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics and mood stabilisers. Prog Neuropsychopharmacol Biol Psychiatry 2006 30 : 1442 52.
33. Lewis SW, Barnes TR, Davies L, et al. Randomised controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006 32 : 715 23.
34. Mayoral F, Montejo AL, Bousono M, et al Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study Actas Esp Psiquiatr 2006 34 : 7 15 Spanish J, Freemantale N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 321 : 1371 6.
35. Kilian R, Angermyer MC. The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic conditions: an application of random effect regression models and propensity scores in an observational prospective trial. Qual Life Res 2005 14 : 1275 89.
36. Jones PB, Barnes TR, Davies L, et al. Randomised controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic drugs in Schizophrenia (CUtLASS 1). Arch Gen Psychiatry 2006 63 : 1079 87.
37. Malla A, Williams R, Kopala L, et al. Outcome on quality of life in a Canadian national sample of patients with schizophrenia and related psychotic disorders. Acta Psychiatr Scand 2006 430 (Suppl. S22 8.
38. Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult SF12 sample. Qual Life Res 1998 7 : 155 66.